MRK
ACC gave Merck a little swagger
Merck came into the American College of Cardiology meeting with a story to tell: the company’s cardiovascular pipeline isn’t just a side quest, it’s part of the game plan. And the star of the show was sotatercept, the PAH drug Merck got via its $11.5 billion purchase of Acceleron Pharma.
The numbers investors actually care about
In the phase 3 STELLAR trial, sotatercept improved the six-minute walk distance by 40.8 meters at week 24 when added to stable background therapy. That kind of result is the sort of thing drugmakers hope turns into a regulatory nod, a new prescription franchise, and eventually, real sales that show up on the income statement.
Why this isn’t just conference confetti
Merck has been pretty open that it wants its cardiovascular business to become a major revenue pillar, with a goal of $10 billion in annual sales from the franchise starting in 2030. That matters because Keytruda, the cancer blockbuster that keeps Merck’s cash machine humming, won’t stay invincible forever.
The bigger picture
The company also spotlighted MK-0616, its oral cholesterol-lowering drug, as another piece of the puzzle. So if you’re an investor, the takeaway is simple: Merck is trying to build a post-Keytruda world before the clock runs out. Big picture: the heart pipeline is starting to look less like backup and more like plan A.